NextCure Inc (NXTC) - Total Assets
Based on the latest financial reports, NextCure Inc (NXTC) holds total assets worth $39.61 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check NextCure Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
NextCure Inc - Total Assets Trend (2017–2024)
This chart illustrates how NextCure Inc's total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of NextCure Inc to evaluate the quality of earnings relative to operating cash generation.
NextCure Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
NextCure Inc's total assets of $39.61 Million consist of 88.8% current assets and 11.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.3% |
| Accounts Receivable | $300.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how NextCure Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of NextCure Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NextCure Inc's current assets represent 88.8% of total assets in 2024, an increase from 48.4% in 2017.
- Cash Position: Cash and equivalents constituted 34.3% of total assets in 2024, down from 43.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
NextCure Inc Competitors by Total Assets
Key competitors of NextCure Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
NextCure Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.97 | 9.07 | 27.89 |
| Quick Ratio | 2.97 | 9.07 | 27.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $21.64 Million | $70.02 Million | $277.65 Million |
NextCure Inc - Advanced Valuation Insights
This section examines the relationship between NextCure Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.93 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -36.8% |
| Total Assets | $80.86 Million |
| Market Capitalization | $7.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values NextCure Inc's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: NextCure Inc's assets decreased by 36.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NextCure Inc (2017–2024)
The table below shows the annual total assets of NextCure Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $80.86 Million | -36.85% |
| 2023-12-31 | $128.04 Million | -30.47% |
| 2022-12-31 | $184.16 Million | -24.02% |
| 2021-12-31 | $242.39 Million | -20.96% |
| 2020-12-31 | $306.64 Million | -13.90% |
| 2019-12-31 | $356.17 Million | +141.26% |
| 2018-12-31 | $147.63 Million | +658.35% |
| 2017-12-31 | $19.47 Million | -- |
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leuke… Read more